FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4252567194> ?p ?o ?g. }

• W4252567194 abstract "Background There are a limited number of treatment options for patients with ulcerative colitis (UC). An increased risk of thrombosis in UC coupled with an observation that UC patients being treated with anticoagulant therapy for thrombotic events had an improvement in their bowel symptoms led to trials examining the use of unfractionated heparin (UFH) and low molecular weight heparins (LMWH) in patients with active UC. Objectives To review randomized trials examining the efficacy of unfractionated heparin (UFH) or low molecular weight heparins (LMWH) for remission induction in patients with ulcerative colitis. Search methods We searched MEDLINE, EMBASE, CENTRAL, and the Cochrane IBD/FBD group specialized trials register up to June 2014. We also searched review papers on ulcerative colitis and references from identified papers in an effort to identify additional randomized trials studying UFH or LMWH use in patients with ulcerative colitis. We searched abstracts from major gastroenterological meetings to identify research published in abstract form. Selection criteria Randomized controlled trials comparing UFH or LMWH to placebo or a control therapy for induction of remission in ulcerative colitis were included. Studies published in abstract form only were included if the authors could be contacted for further information. Data collection and analysis A data extraction form was developed and used to extract data from included studies. Two authors independently extracted data. Any disagreements were resolved by consensus. The Cochrane Risk of Bias tool was used to assess study quality. Data were analyzed on an intention‐to‐treat basis. The primary outcome was induction of remission, as defined by the studies. Secondary outcomes measures included: endoscopic remission as defined by the authors; clinical, histological or endoscopic improvement as defined by the authors; the occurrence of adverse events; the occurrence of bleeding; and improvements in quality of life as measured by a validated instrument. We calculated the risk ratio (RR) and corresponding 95% confidence interval for dichotomous outcomes. Data were combined for analysis if they assessed the same treatments (UFH or LMWH versus placebo or other therapy). The overall quality of the evidence supporting the outcomes was evaluated using the GRADE criteria. Main results Five studies were eligible for inclusion (329 patients). Three studies (270 patients) compared low molecular weight heparin to placebo, one study (34 patients) compared LMWH in addition to standard therapy, and one study (25 patients) compared UFH to corticosteroids. The study comparing UFH to corticosteroids was rated at high risk of bias due to a single‐blind design. The study that compared the addition of LMWH to standard therapy to standard therapy alone was rated at high risk of bias due to open‐label design. The other three studies were rated as low risk of bias. LMWH administered subcutaneously showed no benefit over placebo for any outcome, including clinical remission (very low quality of evidence), and clinical, endoscopic, or histological improvement. High dose LMWH administered via an extended colon‐release tablet demonstrated benefit over placebo for clinical remission (RR 1.39; 95% CI 1.09 to 1.77 ; P = 0.008; very low quality of evidence), clinical improvement (RR 1.28; 95% CI 1.06 to 1.55; P = 0.01; very low quality of evidence), and endoscopic improvement (RR 1.21; 95% CI 1.00 to 1.47 ; P = 0.05) but not endoscopic remission or histologic improvement. LMWH was not beneficial when added to standard therapy for clinical remission, clinical improvement, endoscopic remission or endoscopic improvement. LMWH was well‐tolerated but provided no significant benefit for quality of life. One study examining UFH versus corticosteroids for the treatment of severe UC demonstrated the inferiority of UFH for clinical improvement. More patients assigned to UFH had rectal hemorrhage as an adverse event. Authors' conclusions There is evidence to suggest that LMWH may be effective for the treatment of active UC. When administered by extended colon‐release tablets, LMWH was more effective than placebo for treating outpatients with mild to moderate disease. This benefit needs to be confirmed by further randomized controlled studies. The same benefits were not seen when LMWH was administered subcutaneously at lower doses. There is no evidence to support the use of UFH for the treatment of active UC. A further trial of UFH in patients with mild disease may also be justified. Any benefit found would need to be weighed against a possible increased risk of rectal bleeding in patients with active UC." @default.
• W4252567194 created "2022-05-12" @default.
• W4252567194 creator A5036883744 @default.
• W4252567194 creator A5065846093 @default.
• W4252567194 creator A5065999911 @default.
• W4252567194 creator A5066134129 @default.
• W4252567194 date "2015-08-05" @default.
• W4252567194 modified "2023-09-29" @default.
• W4252567194 title "Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis" @default.
• W4252567194 cites W1481203341 @default.
• W4252567194 cites W1499566049 @default.
• W4252567194 cites W1828984482 @default.
• W4252567194 cites W1946857044 @default.
• W4252567194 cites W1971918462 @default.
• W4252567194 cites W1980605818 @default.
• W4252567194 cites W1987925515 @default.
• W4252567194 cites W1999666395 @default.
• W4252567194 cites W2013064714 @default.
• W4252567194 cites W2040890002 @default.
• W4252567194 cites W2044490764 @default.
• W4252567194 cites W2047212658 @default.
• W4252567194 cites W2052058263 @default.
• W4252567194 cites W2054106516 @default.
• W4252567194 cites W2054491191 @default.
• W4252567194 cites W2057908819 @default.
• W4252567194 cites W2060058442 @default.
• W4252567194 cites W2060968271 @default.
• W4252567194 cites W2064596993 @default.
• W4252567194 cites W2065114975 @default.
• W4252567194 cites W2070424138 @default.
• W4252567194 cites W2079909796 @default.
• W4252567194 cites W2083913175 @default.
• W4252567194 cites W2107761596 @default.
• W4252567194 cites W2115000032 @default.
• W4252567194 cites W2120383165 @default.
• W4252567194 cites W2124787187 @default.
• W4252567194 cites W2127315329 @default.
• W4252567194 cites W2129398184 @default.
• W4252567194 cites W2135376322 @default.
• W4252567194 cites W2135490115 @default.
• W4252567194 cites W2136284733 @default.
• W4252567194 cites W2141541678 @default.
• W4252567194 cites W2141804997 @default.
• W4252567194 cites W2155279047 @default.
• W4252567194 cites W2166930089 @default.
• W4252567194 cites W2171297959 @default.
• W4252567194 cites W2186530519 @default.
• W4252567194 cites W2299224170 @default.
• W4252567194 cites W2405735814 @default.
• W4252567194 cites W2408621477 @default.
• W4252567194 cites W2411835087 @default.
• W4252567194 cites W2412698582 @default.
• W4252567194 cites W2419492149 @default.
• W4252567194 cites W2420838315 @default.
• W4252567194 cites W26368922 @default.
• W4252567194 cites W300797676 @default.
• W4252567194 cites W4231058187 @default.
• W4252567194 cites W4233413316 @default.
• W4252567194 cites W4242503862 @default.
• W4252567194 cites W4248042439 @default.
• W4252567194 cites W4248069620 @default.
• W4252567194 doi "https://doi.org/10.1002/14651858.cd006774.pub4" @default.
• W4252567194 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35658167" @default.
• W4252567194 hasPublicationYear "2015" @default.
• W4252567194 type Work @default.
• W4252567194 citedByCount "4" @default.
• W4252567194 countsByYear W42525671942020 @default.
• W4252567194 countsByYear W42525671942022 @default.
• W4252567194 countsByYear W42525671942023 @default.
• W4252567194 crossrefType "journal-article" @default.
• W4252567194 hasAuthorship W4252567194A5036883744 @default.
• W4252567194 hasAuthorship W4252567194A5065846093 @default.
• W4252567194 hasAuthorship W4252567194A5065999911 @default.
• W4252567194 hasAuthorship W4252567194A5066134129 @default.
• W4252567194 hasBestOaLocation W42525671942 @default.
• W4252567194 hasConcept C126322002 @default.
• W4252567194 hasConcept C141071460 @default.
• W4252567194 hasConcept C142724271 @default.
• W4252567194 hasConcept C168563851 @default.
• W4252567194 hasConcept C204787440 @default.
• W4252567194 hasConcept C27081682 @default.
• W4252567194 hasConcept C2776207728 @default.
• W4252567194 hasConcept C2776884760 @default.
• W4252567194 hasConcept C2777557582 @default.
• W4252567194 hasConcept C2779134260 @default.
• W4252567194 hasConcept C2780479503 @default.
• W4252567194 hasConcept C71924100 @default.
• W4252567194 hasConcept C90924648 @default.
• W4252567194 hasConceptScore W4252567194C126322002 @default.
• W4252567194 hasConceptScore W4252567194C141071460 @default.
• W4252567194 hasConceptScore W4252567194C142724271 @default.
• W4252567194 hasConceptScore W4252567194C168563851 @default.
• W4252567194 hasConceptScore W4252567194C204787440 @default.
• W4252567194 hasConceptScore W4252567194C27081682 @default.
• W4252567194 hasConceptScore W4252567194C2776207728 @default.
• W4252567194 hasConceptScore W4252567194C2776884760 @default.
• W4252567194 hasConceptScore W4252567194C2777557582 @default.
• W4252567194 hasConceptScore W4252567194C2779134260 @default.
• W4252567194 hasConceptScore W4252567194C2780479503 @default.
• W4252567194 hasConceptScore W4252567194C71924100 @default.

• next